Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $39.00

Enliven Therapeutics (NASDAQ:ELVN) had its target price hoisted by HC Wainwright from $37.00 to $39.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, BTIG Research began coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $38.75.

Enliven Therapeutics Stock Up 0.8 %

ELVN stock opened at $21.08 on Friday. Enliven Therapeutics has a twelve month low of $15.96 and a twelve month high of $30.03. The company has a market cap of $1.03 billion, a P/E ratio of -11.09 and a beta of 1.04. The business has a fifty day moving average of $21.31 and a 200-day moving average of $23.78.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, March 13th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.07. The firm had revenue of $0.03 million for the quarter. As a group, equities research analysts anticipate that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $20.41, for a total transaction of $66,332.50. Following the transaction, the chief financial officer now owns 13,000 shares of the company’s stock, valued at $265,330. This trade represents a 20.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total transaction of $257,625.00. Following the completion of the sale, the insider now directly owns 1,002,688 shares of the company’s stock, valued at $20,665,399.68. The trade was a 1.23 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 72,784 shares of company stock worth $1,610,375. Insiders own 29.20% of the company’s stock.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC grew its stake in Enliven Therapeutics by 230.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after acquiring an additional 1,114 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at approximately $97,000. BNP Paribas Financial Markets acquired a new position in shares of Enliven Therapeutics in the 4th quarter valued at approximately $112,000. ExodusPoint Capital Management LP bought a new stake in Enliven Therapeutics during the 4th quarter worth approximately $200,000. Finally, Brevan Howard Capital Management LP acquired a new stake in Enliven Therapeutics during the 4th quarter worth approximately $228,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.